Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 5/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.41 |
| ▸ | ATR | Q13535 | 13/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16339132 | 0.80 | CYP4F2 (0.40) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL2215449 | 0.78 | CYP4F2 (0.47) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL19579426 | 0.78 | KDM5B (0.37) | CYP4F2CYP4A11 | |
| SCHEMBL28916707 | 0.76 | CYP4F2 (0.42) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL21756659 | 0.75 | CYP4F2 (0.42) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL17501187 | 0.73 | — | — | |
| SCHEMBL2839522 | 0.72 | CYP4F2 (0.42) | CYP4F2CYP4A11ATR | |
| SCHEMBL878070 | 0.71 | — | — | |
| SCHEMBL22951244 | 0.70 | CYP4F2 (0.47) | CYP4F2CYP4A11ATRRXRARXRB | |
| SCHEMBL30739025 | 0.70 | CYP4F2 (0.44) | CYP4F2CYP4A11ATRRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258343-B2 | Method for preparing 2-[(3R)-3-methylmorpholin-4-yl]-4-[1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-25 | — | — | US | claimed |
| CN-116041349-B | Xanthine compound, preparation method thereof and application thereof in preparation of novel coronavirus 3CL protease inhibitor | 吉斯凯(苏州)制药有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-112823158-B | Process for preparing 2- [ (3R) -3-methylmorpholin-4-yl ] -4- (1-methyl-1H-pyrazol-5-yl) -8- (1H-pyrazol-5-yl) -1, 7-naphthyridine | 拜耳股份有限公司 | 2023-08-15 | — | — | CN | claimed |
| EP-3841101-B1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | BAYER AG (DE) | 2023-05-03 | — | — | EP | claimed |
| CN-116041349-A | Xanthine compound, preparation method thereof and application thereof in preparation of novel coronavirus 3CL protease inhibitor | 吉斯凯(苏州)制药有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-20210253573-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-19 | — | — | US | claimed |
| CN-112823158-A | Process for the preparation of 2- [ (3R) -3-methylmorpholin-4-yl ] -4- (1-methyl-1H-pyrazol-5-yl) -8- (1H-pyrazol-5-yl) -1, 7-naphthyridine | 拜耳股份有限公司 | 2021-05-18 | — | — | CN | claimed |
| US-12617791-B2 | Triheterocyclic derivative, and pharmaceutical composition and application thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-12583840-B2 | Method for the preparation of androgen receptor antagonists and intermediates thereof | ORION CORPORATION (FI) | 2026-03-24 | — | — | US | disclosed |
| EP-4695236-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4230628-B1 | TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2025-10-15 | — | — | EP | disclosed |
| US-12338243-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-24 | — | — | US | disclosed |
| US-20250101040-A1 | NEW TYPE PYRAZOLOPYRIMIDINE COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Yayo Biotechnology Co., Ltd. (CN) | 2025-03-27 | — | — | US | disclosed |
| EP-2493858-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2012-09-05 | — | — | EP | disclosed |
| EP-2486004-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen Corporation (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN RESEARCH NV (BE) | 2012-08-09 | — | — | US | disclosed |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| WO-2011051540-A9 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011051540-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011044506-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101040-A1 | NEW TYPE PYRAZOLOPYRIMIDINE COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, ATR, WEE2 | CYP4F2 225/4885CYP4A11 300/4885ATR 2/4885 |
| US-12338243-B2 | P2X7 modulators | P2RX7, P2RX4, P2RX1 | CYP4F2 841/4885CYP4A11 149/4885ATR 4054/4885 |
| US-12583840-B2 | Method for the preparation of androgen receptor antagonists and intermediates thereof | AR, FSHR, PKD1 | CYP4F2 2009/4885CYP4A11 1079/4885ATR 459/4885 |
| US-12258343-B2 | Method for preparing 2-[(3R)-3-methylmorpholin-4-yl]-4-[1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine | CYP1B1, CYP4B1, CYP1A1 | CYP4F2 137/4885CYP4A11 46/4885ATR 4527/4885 |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | CYP4F2 2373/4885CYP4A11 649/4885ATR 3987/4885 |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | CYP4F2 3677/4885CYP4A11 3300/4885ATR 4196/4885 |
| US-12617791-B2 | Triheterocyclic derivative, and pharmaceutical composition and application thereof | ATR, NR3C1, NR5A1 | CYP4F2 1555/4885CYP4A11 244/4885ATR 1/4885 |
| US-20210253573-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | CYP1B1, CYP4B1, CYP1A1 | CYP4F2 137/4885CYP4A11 46/4885ATR 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.